# US 2026/0308275 A1 · Hybrid transient transfection using transposase for high yield product production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0308275 A1
- Document ID: US20260308275A1
- Status: Published application
- Kind: A1
- Application number: 19/482,323
- Filed: 2024-05-09
- Published: 2026-10-08
- Earliest claimed: 2023-05-12
- Assignees: Lonza Biologics PLC; Lonza Houston, Inc.
- Applicants: Lonza Biologics PLC; Lonza Houston, Inc.
- Inventors: Peter M. O’CALLAGHAN; Bernadette SWEENEY; James HARVEY; Devarshi KAPADIA
- Web page: https://patentgrep.com/patent/US20260308275A1

## CPC

- C07K 16/32: against translation products of oncogenes
- C12N 15/86: Viral vectors
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15051: Methods of production or purification of viral material
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of producing a protein of interest, comprising: providing a host cell, a vector comprising a nucleic acid sequence encoding the protein of interest, and a transposase; transfecting the host cell using the vector and the transposase to obtain a transfected cell; culturing the transfected cell to form a culture; and harvesting the culture to obtain the protein of interest from the harvested culture, wherein cells of the culture are not passaged prior to harvesting the culture.

## Claims

### Claim 1

A method of producing a protein of interest, comprising:
providing a host cell, a vector comprising a nucleic acid sequence encoding the protein of interest, and a transposase;
transfecting the host cell using the vector and the transposase to obtain a transfected cell;
culturing the transfected cell to form a culture; and
harvesting the culture to obtain the protein of interest from the harvested culture,
wherein cells of the culture are not passaged prior to harvesting the culture.

### Claim 2 (depends on 1)

The method of claim 1, wherein the host cell comprises a mammalian cell line.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell line, a baby hamster kidney (BHK) cell line, a murine myeloma cell line, a human embryonic kidney cell line (HEK) cell line, or a HeLa cell line.

### Claim 4 (depends on 1)

The method of claim 1, wherein the host cell comprises a CHOK1 SV GS-knock out cell line.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the host cell is pre-cultured for about 4 days to about 28 days to form a pre-culture before the transfecting.

### Claim 6 (depends on 5)

The method of claim 5, wherein the host cell is pre-cultured in a chemically defined Chinese hamster Ovary (CD CHO) medium supplemented with 6 mM glutamine before transfection.

### Claim 7 (depends on 5, 6)

The method of claim 5 or claim 6, wherein the pre-culture has at least 90% cell viability.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the vector comprises an adenoviral vector, a pSV vector, a pCMV vector, a vaccinia vector, a retroviral vector, or a baculovirus vector.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the vector comprises a glutamine synthetase gene.

### Claim 10 (depends on 9)

The method of claim 9, wherein the vector comprises a hyperactive super PIGGYBAC® inverted terminal repeat (ITR) sequence.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1 to 10, wherein the vector comprises one to about 5 nucleic acid sequences encoding the protein of interest, or the vector comprises one to about 5 different vectors comprising the nucleic acid sequence.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the transposase comprises an RNase H-like transposase, a HUH single-stranded DNA transposase, a serine transposase, a tyrosine transposase, a PIGGYBAC® transposase, or a combination thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the transposase comprises a PIGGYBAC® transposase.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein the transposase is contained in a transposase vector or delivered as mRNA.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14, wherein transfecting the host cell is performed using polyethylenimine (PEI), lipofection, electroporation, magnetofection, microinjection, gene gun insertion, impalefection, hydrostatic pressure, or sonication.

### Claim 16 (depends on 15)

The method of claim 15, wherein transfecting the host cell is performed using PEI.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the transfected cells are cultured in a medium, and the medium comprises Dulbecco's Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640, Minimum Essential Medium (MEM), a chemically defined Chinese hamster Ovary (CD CHO) medium without supplementing glutamine, or a combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the medium comprises CD CHO medium without supplementing glutamine.

### Claim 19 (depends on 18)

The method of claim 18, wherein the culture is devoid of methionine sulfoxamine (MSX).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the culture is bolus fed at day 2 and day 5 after transfecting the host cell.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1 to 20, wherein transfecting occurs on day 1 and harvesting begins on day 2 of the method.

### Claim 22 (depends on 21)

The method of claim 21, wherein harvesting continues from day 2 to at least day 14 of the method.

### Claim 23

A method of producing a protein of interest, comprising:
providing a host cell, a vector comprising a nucleic acid sequence encoding the protein of interest, and a transposase;
transfecting the host cell using the vector and the transposase to obtain a transfected cell;
culturing the transfected cell to form a culture; and
harvesting the culture to obtain the protein of interest from the harvested culture,
wherein cells of the culture are of the same cell lineage as the transfected cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein the host cell comprises a mammalian cell line.

### Claim 25 (depends on 24)

The method of claim 24, wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell line, a baby hamster kidney (BHK) cell line, a murine myeloma cell line, a human embryonic kidney cell line (HEK) cell line, or a HeLa cell line.

### Claim 26 (depends on 23)

The method of claim 23, wherein the host cell comprises a CHOK1SV GS-knock out cell line.

### Claim 27 (depends on 23, 24, 25, 26)

The method of any one of claims 23 to 26, wherein the host cell is pre-cultured for about 4 days to about 28 days to form a pre-culture before the transfecting.

### Claim 28 (depends on 27)

The method of claim 27, wherein the host cell is pre-cultured in a chemically defined Chinese hamster Ovary (CD CHO) medium supplemented with 6 mM glutamine before transfection.

### Claim 29 (depends on 27, 28)

The method of claim 27 or claim 28, wherein the pre-culture has at least 90% cell viability.

### Claim 30 (depends on 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 23 to 29, wherein the vector comprises an adenoviral vector, a pSV vector, a pCMV vector, a vaccinia vector, a retroviral vector, or a baculovirus vector.

### Claim 31 (depends on 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 23 to 30, wherein the vector comprises a glutamine synthetase gene.

### Claim 32 (depends on 31)

The method of claim 31, wherein the vector comprises a hyperactive super PIGGYBAC® inverted terminal repeat (ITR) sequence.

### Claim 33 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 23 to 32, wherein the vector comprises one to about 5 nucleic acid sequences encoding the protein of interest, or the vector comprises one to about 5 different vectors comprising the nucleic acid sequence.

### Claim 34 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 23 to 33, wherein the transposase comprises an RNase H-like transposase, a HUH single-stranded DNA transposase, a serine transposase, a tyrosine transposase, a PIGGYBAC® transposase, or a combination thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the transposase comprises a PIGGYBAC® transposase.

### Claim 36 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 23 to 35, wherein the transposase is contained in a transposase vector.

### Claim 37 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 23 to 36, wherein the transfecting the host cell is performed using polyethylenimine (PEI), lipofection, electroporation, magnetofection, microinjection, gene gun insertion, impalefection, hydrostatic pressure, or sonication.

### Claim 38 (depends on 37)

The method of claim 37, wherein the transfecting the host cell is performed using PEI.

### Claim 39 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 23 to 38, wherein the transfected cells are cultured in a medium, and the medium comprises Dulbecco's Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640, Minimum essential medium (MEM), a chemically defined Chinese hamster Ovary (CD CHO) medium without supplementing glutamine, or a combination thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein the medium comprises CD CHO medium without supplementing glutamine.

### Claim 41 (depends on 40)

The method of claim 40, wherein the culture is devoid of methionine sulfoxamine (MSX).

### Claim 42 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 23 to 41, wherein the culture is bolus fed at day 2 and day 5 after transfecting the host cell.

### Claim 43 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 23 to 42, wherein the transfecting occurs on day 1 and the harvesting begins on day 2 of the method.

### Claim 44 (depends on 43)

The method of claim 43, wherein the harvesting continues from day 2 to at least day 14 of the method.

### Claim 45

A method of producing a viral gene of interest, comprising:
providing a host cell, a vector comprising a nucleic acid sequence encoding the viral gene of interest, and a transposase;
transfecting the host cell using the vector and the transposase to obtain a transfected cell;
culturing the transfected cell to form a culture; and
harvesting the culture to obtain the viral gene of interest from the harvested culture,
wherein cells of the culture are not passaged prior to harvesting the culture.

### Claim 46 (depends on 45)

The method of claim 45, wherein the viral gene of interest produces an AAV virus particle or a lentivirus particle.
